Lv41
790 积分 2025-02-25 加入
Golidocitinib and chidamide for refractory or relapsed peripheral T-cell lymphoma: A preliminary cost-effectiveness analysis in China
1小时前
已完结
Emerging therapeutic strategies for mature T-cell and natural killer-cell lymphomas
4小时前
已完结
Golidocitinib and chidamide for refractory or relapsed peripheral T-cell lymphoma: A preliminary cost-effectiveness analysis in China
7天前
已完结
Pralatrexate and total skin electron beam therapy as bridging agents to allogeneic stem cell transplantation in severely treatment-refractory Sezary syndrome
10天前
已完结
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
18天前
已完结
Inhibition of EZH2 by SHR2554 modifies subset ratios and suppresses polyfunctional responses of peripheral blood T cells from hematopoietic stem cell donors
18天前
已完结
Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma
1个月前
已完结
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study
1个月前
已完结
A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk Stratification
1个月前
已完结
Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia
1个月前
已完结
皖公网安备34019202002308
